Switch theme
Sign up to access all valuation multiples
4DMedical Ltd is a company focused on medical research technology and the development of a non-invasive respiratory imaging solution using four-dimensional imaging. The four-dimensional lung imaging technology utilizes mathematical models and algorithms to convert X-ray scans into quantitative data, aiding physicians in managing patients with respiratory and lung diseases.
2012
145
LTM Revenue $4.6M
LTM EBITDA -$20.2M
$94.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
4DMedical has a last 12-month revenue (LTM) of $4.6M and a last 12-month EBITDA of -$20.2M.
In the most recent fiscal year, 4DMedical achieved revenue of $2.0M and an EBITDA of -$20.5M.
4DMedical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See 4DMedical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.6M | XXX | $2.0M | XXX | XXX | XXX |
| Gross Profit | -$8.1M | XXX | $1.8M | XXX | XXX | XXX |
| Gross Margin | -176% | XXX | 92% | XXX | XXX | XXX |
| EBITDA | -$20.2M | XXX | -$20.5M | XXX | XXX | XXX |
| EBITDA Margin | -437% | XXX | -1045% | XXX | XXX | XXX |
| EBIT | -$23.3M | XXX | -$29.9M | XXX | XXX | XXX |
| EBIT Margin | -505% | XXX | -1528% | XXX | XXX | XXX |
| Net Profit | -$22.9M | XXX | -$23.1M | XXX | XXX | XXX |
| Net Margin | -497% | XXX | -1180% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, 4DMedical's stock price is AUD 0 (or $0).
4DMedical has current market cap of AUD 158M (or $102M), and EV of AUD 147M (or $94.5M).
See 4DMedical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $94.5M | $102M | XXX | XXX | XXX | XXX | $-0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, 4DMedical has market cap of $102M and EV of $94.5M.
4DMedical's trades at 27.9x EV/Revenue multiple, and -4.6x EV/EBITDA.
Equity research analysts estimate 4DMedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
4DMedical has a P/E ratio of -4.4x.
See valuation multiples for 4DMedical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $102M | XXX | $102M | XXX | XXX | XXX |
| EV (current) | $94.5M | XXX | $94.5M | XXX | XXX | XXX |
| EV/Revenue | 20.5x | XXX | 27.9x | XXX | XXX | XXX |
| EV/EBITDA | -4.7x | XXX | -4.6x | XXX | XXX | XXX |
| EV/EBIT | -4.0x | XXX | -3.5x | XXX | XXX | XXX |
| EV/Gross Profit | -11.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -4.4x | XXX | -4.4x | XXX | XXX | XXX |
| EV/FCF | -5.7x | XXX | -5.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free Trial4DMedical's last 12 month revenue growth is 198%
4DMedical's revenue per employee in the last FY averaged $14K, while opex per employee averaged $0.2M for the same period.
4DMedical's rule of 40 is -1615% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
4DMedical's rule of X is 59% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for 4DMedical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 198% | XXX | 170% | XXX | XXX | XXX |
| EBITDA Margin | -437% | XXX | -601% | XXX | XXX | XXX |
| EBITDA Growth | -47% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1615% | XXX | -402% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $14K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1621% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
4DMedical acquired XXX companies to date.
Last acquisition by 4DMedical was XXXXXXXX, XXXXX XXXXX XXXXXX . 4DMedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was 4DMedical founded? | 4DMedical was founded in 2012. |
| Where is 4DMedical headquartered? | 4DMedical is headquartered in Australia. |
| How many employees does 4DMedical have? | As of today, 4DMedical has 145 employees. |
| Is 4DMedical publicy listed? | Yes, 4DMedical is a public company listed on ASX. |
| What is the stock symbol of 4DMedical? | 4DMedical trades under 4DX ticker. |
| When did 4DMedical go public? | 4DMedical went public in 2020. |
| Who are competitors of 4DMedical? | Similar companies to 4DMedical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of 4DMedical? | 4DMedical's current market cap is $102M |
| What is the current revenue of 4DMedical? | 4DMedical's last 12 months revenue is $4.6M. |
| What is the current revenue growth of 4DMedical? | 4DMedical revenue growth (NTM/LTM) is 198%. |
| What is the current EV/Revenue multiple of 4DMedical? | Current revenue multiple of 4DMedical is 20.5x. |
| Is 4DMedical profitable? | Yes, 4DMedical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of 4DMedical? | 4DMedical's last 12 months EBITDA is -$20.2M. |
| What is 4DMedical's EBITDA margin? | 4DMedical's last 12 months EBITDA margin is -437%. |
| What is the current EV/EBITDA multiple of 4DMedical? | Current EBITDA multiple of 4DMedical is -4.7x. |
| What is the current FCF of 4DMedical? | 4DMedical's last 12 months FCF is -$16.6M. |
| What is 4DMedical's FCF margin? | 4DMedical's last 12 months FCF margin is -360%. |
| What is the current EV/FCF multiple of 4DMedical? | Current FCF multiple of 4DMedical is -5.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
